Get started
Astellas Pharma Inc.Astellas Pharma Inc.Astellas Pharma Inc.

Astellas Pharma Inc.

No trades
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsETFs

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.77 T‬ JPY
Dividend yield (indicated)
3.73%
Price to earnings Ratio (TTM)
30.0
Basic EPS (TTM)
69.5 JPY
Net income (FY)
‪50.75 B‬ JPY
Revenue (FY)
‪1.91 T‬ JPY
Shares float
‪1.71 B‬
Beta (1Y)
0.64

Employees


Employees (FY)
‪13.64 K‬
Change (1Y)
‪−1.11 K‬ −7.53%
Revenue / Employee (1Y)
‪140.17 M‬ JPY
Net income / Employee (1Y)
‪3.72 M‬ JPY

About Astellas Pharma Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Naoki Okamura
Website
astellas.com
Headquarters
Tokyo
Founded
1923
Identifiers
2
ISINJP3942400007
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Check out other big names from the same industry as 4503.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs


1306
Next Funds TOPIX Exchange Traded Fund
Weight
0.37%
Market value
‪700.61 M‬
USD
1321
Next Funds Nikkei 225 Exchange Traded Fund
Weight
0.68%
Market value
‪594.16 M‬
USD
1308
Nikko Exchange Traded Index Fund TOPIX
Weight
0.38%
Market value
‪333.90 M‬
USD
VXUS
Vanguard Total International Stock ETF
Weight
0.06%
Market value
‪328.10 M‬
USD
1330
Nikko Exchange Traded Index Fund 225
Weight
0.69%
Market value
‪294.93 M‬
USD
1305
iFreeETF TOPIX
Weight
0.35%
Market value
‪291.95 M‬
USD
VEA
Vanguard FTSE Developed Markets ETF
Weight
0.08%
Market value
‪211.09 M‬
USD
IEFA
iShares Core MSCI EAFE ETF
Weight
0.10%
Market value
‪164.41 M‬
USD
1346
MAXIS Nikkei 225 ETF
Weight
0.69%
Market value
‪139.26 M‬
USD
1489
NEXT FUNDS Nikkei 225 High Dividend Yield Stock 50 Index ETF
Weight
4.07%
Market value
‪123.95 M‬
USD
1348
MAXIS TOPIX ETF
Weight
0.37%
Market value
‪99.55 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of 4503 is 2,099.0 JPY — it has increased by 0.05% in the past 24 hours. Watch Astellas Pharma Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange Astellas Pharma Inc. stocks are traded under the ticker 4503.
4503 stock has fallen by −1.69% compared to the previous week, the month change is a 5.23% rise, over the last year Astellas Pharma Inc. has showed a 38.37% increase.
We've gathered analysts' opinions on Astellas Pharma Inc. future price: according to them, 4503 price has a max estimate of 2,400.00 JPY and a min estimate of 1,300.00 JPY. Watch 4503 chart and read a more detailed Astellas Pharma Inc. stock forecast: see what analysts think of Astellas Pharma Inc. and suggest that you do with its stocks.
4503 reached its all-time high on May 25, 2023 with the price of 2,360.5 JPY, and its all-time low was 512.0 JPY and was reached on Sep 25, 2002. View more price dynamics on 4503 chart.
See other stocks reaching their highest and lowest prices.
4503 stock is 0.88% volatile and has beta coefficient of 0.64. Track Astellas Pharma Inc. stock price on the chart and check out the list of the most volatile stocks — is Astellas Pharma Inc. there?
Today Astellas Pharma Inc. has the market capitalization of ‪3.75 T‬, it has increased by 3.00% over the last week.
Yes, you can track Astellas Pharma Inc. financials in yearly and quarterly reports right on TradingView.
Astellas Pharma Inc. is going to release the next earnings report on Feb 9, 2026. Keep track of upcoming events with our Earnings Calendar.
4503 earnings for the last quarter are 44.22 JPY per share, whereas the estimation was 29.81 JPY resulting in a 48.35% surprise. The estimated earnings for the next quarter are 43.03 JPY per share. See more details about Astellas Pharma Inc. earnings.
Astellas Pharma Inc. revenue for the last quarter amounts to ‪524.32 B‬ JPY, despite the estimated figure of ‪481.09 B‬ JPY. In the next quarter, revenue is expected to reach ‪521.63 B‬ JPY.
4503 net income for the last quarter is ‪79.21 B‬ JPY, while the quarter before that showed ‪68.42 B‬ JPY of net income which accounts for 15.77% change. Track more Astellas Pharma Inc. financial stats to get the full picture.
Astellas Pharma Inc. dividend yield was 5.12% in 2024, and payout ratio reached 261.05%. The year before the numbers were 4.26% and 736.46% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 26, 2025, the company has ‪13.64 K‬ employees. See our rating of the largest employees — is Astellas Pharma Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Astellas Pharma Inc. EBITDA is ‪552.94 B‬ JPY, and current EBITDA margin is 23.78%. See more stats in Astellas Pharma Inc. financial statements.
Like other stocks, 4503 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Astellas Pharma Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Astellas Pharma Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Astellas Pharma Inc. stock shows the strong buy signal. See more of Astellas Pharma Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.